
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Celsion Corp. has received FDA approval to market the Prolieve Thermodilatationsystem for the treatment of BPH symptoms. Boston Scientific will distributeand co-market the treatment.





